中国癌症杂志 ›› 2020, Vol. 30 ›› Issue (3): 166-173.doi: 10.19401/j.cnki.1007-3639.2020.03.002

• 专家述评与论著 • 上一篇    下一篇

中国乳腺癌前哨淋巴结活检现状调查研究

郭 瑢 1 ,李 伦 1 ,张 琪 1 ,修秉虬 1 ,杨犇龙 1 ,王 嘉1 ,苏永辉 1 ,季玮儒 1 ,张莹莹 1 ,邵志敏 1,2 ,吴 炅 1,2   

  1. 1. 复旦大学附属肿瘤医院乳腺外科,复旦大学上海医学院肿瘤学系,上海 200032 ;
    2. 协同创新中心,上海 200032
  • 出版日期:2020-03-30 发布日期:2020-04-03
  • 通信作者: 吴 炅 E-mail: wujiong1122@vip.sina.com
  • 基金资助:
    国家重点研发计划(2017YFC1311004);上海市科学技术委员会优秀学术带头人计划(18XD1401300)。

Current status of sentinel lymph node biopsy for breast cancer in China: a cross-sectional study

GUO Rong 1 , LI Lun 1 , ZHANG Qi 1 , XIU Bingqiu 1 , YANG Benlong 1 , WANG Jia 1 , SU Yonghui 1 , JI Weiru 1 , ZHANG Yingying 1 , SHAO Zhimin 1,2 , WU Jiong 1,2   

  1. 1. Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; 2. Collaborative Innovation Center for Cancer Medicine, Shanghai 200032, China
  • Published:2020-03-30 Online:2020-04-03
  • Contact: WU Jiong E-mail: wujiong1122@vip.sina.com

摘要: 背景与目的:前哨淋巴结活检(sentinel lymph node biopsy,SLNB)已经成为乳腺癌临床腋窝淋巴结阴性患者的标准腋窝分期方案。由中国抗癌协会乳腺癌专业委员会发起的SLNB调查研究,旨在了解中国大型医院乳腺癌SLNB的开展现状。方法:在全国范围内纳入2017年手术量大于200例的医院,共110家医院完成问卷调查。调查问卷包括SLNB的开展现状、免除腋窝清扫及新辅助化疗(neoadjuvant chemotherapy,NAC)中SLNB的应用等热点问题。采用χ 2 检验、Fisher确切概率法或Kolmogorov-Smirnov检验对数据进行分析。结果:参与调研的110家医院均开展了SLNB,其中,85家(77.27%)医院对超过50%的临床腋窝淋巴结阴性(cN 0 )乳腺癌患者常规进行SLNB。肿瘤专科医院(χ 2 =5.62,P=0.018)、保乳手术(breast-conserving surgery,BCS)量较大的医院(D=0.33,P=0.032)开展SLNB的比例更高。大部分医院(93/110,84.55%)未开展内乳SLNB。最常用的示踪方法为染料(主要是亚甲蓝,69/110,62.73%),仅14.55%(16/110)的医院使用核素联合染料双示踪法。几乎所有的医院(107/110,97.27%)均采用术中快速冰冻切片对前哨淋巴结(sentinel lymph node,SLN)进行病理学诊断。对于cN 0 、SLN 1~2枚转移的BCS患者,大部分医院(61/110,55.45%)仅对少于10%的该类患者免除后续腋窝淋巴结清扫(axillary lymph node dissection,ALND)。对于cN 0 、SLN 1~2枚转移的全乳切除患者,84家(76.36%)医院对少于10%的此类患者免除后续ALND。对于接受NAC的患者,50家(45.45%)医院在NAC后进行SLNB,60家(54.55%)医院在NAC前进行SLNB。行NAC较多的医院(χ 2 =4.365,P=0.037)、在NAC期间常规使用磁共振成像(magnetic resonance imaging,MRI)评估的医院(χ 2 =10.967,P=0.004),更倾向于在NAC后行SLNB。结论:尽管示踪剂的规范应用尚有待改进,早期乳腺癌患者的SLNB已经成为中国评估腋窝状态的标准方式。对于SLN转移负荷较低的患者,国内学者对于免于腋窝清扫仍较为保守。接受NAC的患者,SLNB的应用时机仍存在争议。

关键词: 乳腺癌, 前哨淋巴结活检, 问卷调查

Abstract: Background and purpose: Sentinel lymph node biopsy (SLNB) has become the standard axillary staging procedure for clinically nodal-negative (cN 0 ) breast cancer patients. This study was sponsored by the Chinese Anti-Cancer Association, Committee of Breast Cancer Society and aimed to explore the current clinical practice of SLNB in large hospitals in China. Methods: A total of 110 hospitals with more than 200 breast cancer operations in 2017 were included, and finally a total of 110 hospitals completed the questionnaire survey. The questionnaire included the current status of SLNB, the acceptance of omitting axillary lymph node dissection (ALND) and the use of SLNB in neoadjuvant chemotherapy (NAC). Data were analyzed using χ 2 test, Fisher’s exact test or Kolmogorov-Smirnov test. Results: All the hospitals included in the study performed SLNB. A total of 85 (77.27%) hospitals routinely performed SLNB for more than 50% of patients with clinically axillary node-negative breast cancer. The proportion of SLNB in cancer centers (χ 2 =5.62, P=0.018) and hospitals with more breast-conserving surgery (BCS) performed (D=0.33, P=0.032) was higher. Internal mammary sentinel lymph node biopsy (IM-SLNB) was not available in most of the hospitals (93/110, 84.55%). As for the choice of mapping agent, most of the hospitals (69/110, 62.7%) used methylene blue alone, while 14.5% (16/110) hospitals used methylene blue and radioisotope simultaneously. Almost all the hospitals (107/110, 97.27%) used intraoperative frozen section for pathological diagnosis of sentinel lymph node (SLN). Most of the hospitals (61/110,55.45%) accepted omitting ALND for less than 10% of cN 0 patients with 1 or 2 positive SLNs who received BCS. A total of 84 hospitals (76.36%) performed ALND for less than 10% of those patients with clinically axillary node-negative breast cancer, mastectomy and 1-2 metastatic SLNs. Fifty (45.45%) hospitals performed SLNB after NAC, and other 60 (54.55%) hospitals performed SLNB before NAC. Hospitals with more NAC performed (χ 2 =4.365, P=0.037) and magnetic resonance imaging (MRI) routinely used for NAC assessment (χ 2 =10.967, P=0.004) were more inclined to perform SLNB after NAC. Conclusion: Although the standard application of mapping agent needs to be improved, SLNB has become the standard surgical procedure for early breast cancer patients in China. For breast cancer patients with low sentinel lymph node metastasis load, domestic surgeons are still relatively conservative in omitting ALND. The timing of SLNB in patients who received NAC is still controversial.

Key words: Breast cancer, Sentinel lymph node biopsy, Questionnaire survey